Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease
Science Advances · 2024
DOI: 10.1126/sciadv.adn6068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Swayam Prakash Srivastava und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 4, Diabetic Nephropathies, Podocytes, Fibrosis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Angiopoietin-like 4 (ANGPTL4), a key protein involved in lipoprotein metabolism, has diverse effects. There is an association between Angptl4 and diabetic kidney disease; however, this association has not been well investigated. We show that both podocyte- and tubule-specific ANGPTL4 are crucial fibrogenic molecules in diabetes. Diabetes accelerates the fibrogenic phenotype in control mice but not in ANGPTL4 mutant mice. The protective effect observed in ANGPTL4 mutant mice is correlated with a reduction in stimulator of interferon genes pathway activation, expression of pro-inflammatory cytokines, reduced epithelial-to-mesenchymal transition and endothelial-to-mesenchymal transition, lessened mitochondrial damage, and increased fatty acid oxidation. Mechanistically, we demonstrate that podocyte- or tubule-secreted Angptl4 interacts with Integrin β1 and influences the association between dipeptidyl-4 with Integrin β1. We demonstrate the utility of a targeted pharmacologic therapy that specifically inhibits Angptl4 gene expression in the kidneys and protects diabetic kidneys from proteinuria and fibrosis. Together, these data demonstrate that podocyte- and tubule-derived Angptl4 is fibrogenic in diabetic kidneys.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA.
- Vascular Biology and Therapeutics Program, Yale University, New Haven, CT, USA.
- Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
- Department of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Japan.
- Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
- Department of Medicine (Cardiology), The Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID-Profile: Swayam Prakash Srivastava, Myshal Morris, Begoña Lainez-Mas, Leigh Goedeke, Barani Kumar Rajendran, Ken Inoki, Alan Dardik, Gerald I Shulman, Julie E Goodwin
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NIGMS NIH HHS
- NCATS NIH HHS
Zitieren
APA
Srivastava, S. P., Zhou, H., Shenoi, R., Morris, M., Lainez-Mas, B., Goedeke, L., Rajendran, B. K., Setia, O., Aryal, B., Kanasaki, K., Koya, D., Inoki, K., Dardik, A., Bell, T., Fernández-Hernando, C., Shulman, G. I., & Goodwin, J. E. (2024). Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. Science Advances. https://doi.org/10.1126/sciadv.adn6068
Vancouver
Srivastava SP, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, et al. Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. Science Advances. 2024. doi:10.1126/sciadv.adn6068
BibTeX
@article{Srivastava2024,
author = {Srivastava, Swayam Prakash and Zhou, Han and Shenoi, Rachel and Morris, Myshal and Lainez-Mas, Begoña and Goedeke, Leigh and Rajendran, Barani Kumar and Setia, Ocean and Aryal, Binod and Kanasaki, Keizo and Koya, Daisuke and Inoki, Ken and Dardik, Alan and Bell, Thomas and Fernández-Hernando, Carlos and Shulman, Gerald I and Goodwin, Julie E},
title = {Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adn6068}
}
EUVIMED